[Therapy-related AML(M2) with t(8;21) that developed three years after chemotherapy for hepatocellular carcinoma]

Rinsho Ketsueki. 1996 May;37(5):448-51.
[Article in Japanese]

Abstract

A 60-year-old male with hepatocellular carcinoma was treated by repeated intra-arterial injection of epirubicin, carboplatin and doxorubicin. Subsequently, radiotherapy and intravenous administration of etoposide were also carried out. Thirty-three months later he developed AML (M2). The chromosome analysis revealed 45, X, -Y, t (8;21) (q22;q22), which suggested that this leukemia was induced by topoisomerase II targeting agents. He was treated with low dose BHAC and G-CSF and achieved complete remission. This leukemia may be caused by synergic effect of topoisomerase II inhibitors and carboplatin together with radiotherapy. This may be the first report of therapy-related leukemia following chemotherapy for hepatocellular carcinoma.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Carboplatin / adverse effects
  • Carcinoma, Hepatocellular / drug therapy*
  • Chromosomes, Human, Pair 21*
  • Chromosomes, Human, Pair 8*
  • Doxorubicin / adverse effects
  • Epirubicin / adverse effects
  • Etoposide / adverse effects
  • Humans
  • Leukemia, Myeloid, Acute / chemically induced*
  • Leukemia, Myeloid, Acute / genetics
  • Liver Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Neoplasms, Second Primary / chemically induced*
  • Neoplasms, Second Primary / genetics
  • Translocation, Genetic*

Substances

  • Epirubicin
  • Etoposide
  • Doxorubicin
  • Carboplatin